These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 19774844)

  • 1. Importance of leuprolide acetate variable dosing for precocious puberty: a range of acceptable suppression.
    Cohen D; Janfaza M; Klein KO
    J Pediatr Endocrinol Metab; 2009 Jul; 22(7):629-34. PubMed ID: 19774844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment?
    Kunz GJ; Sherman TI; Klein KO
    J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1189-98. PubMed ID: 18183790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
    Neely EK; Hintz RL; Parker B; Bachrach LK; Cohen P; Olney R; Wilson DM
    J Pediatr; 1992 Oct; 121(4):634-40. PubMed ID: 1403402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
    Lanes R; Soros A; Jakubowicz S
    J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated Random Luteinizing Hormone is an Unreliable Indicator for Pubertal Suppression in Girls Treated with Monthly Leuprolide for Idiopathic Central Precocious Puberty.
    Wiromrat P; Panamonta O
    J Clin Res Pediatr Endocrinol; 2019 Sep; 11(3):227-233. PubMed ID: 30592192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of bone maturation, growth rate and adult height in children with central precocious puberty treated with depot leuprolide acetate.
    Klein KO; Dragnic S; Soliman AM; Bacher P
    J Pediatr Endocrinol Metab; 2018 Jun; 31(6):655-663. PubMed ID: 29750651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
    Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
    Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of leuprolide therapy in children with central precocious puberty.
    Kappy MS; Stuart T; Perelman A
    Am J Dis Child; 1988 Oct; 142(10):1061-4. PubMed ID: 3140654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty.
    Lee HS; Yoon JS; Roh JK; Hwang JS
    Endocrine; 2016 Nov; 54(2):497-503. PubMed ID: 27444748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
    Lee PA; Klein K; Mauras N; Neely EK; Bloch CA; Larsen L; Mattia-Goldberg C; Chwalisz K
    J Clin Endocrinol Metab; 2012 May; 97(5):1572-80. PubMed ID: 22344198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of central precocious puberty treatment with GnRH analogue at the Triangulo Mineiro Federal University (UFTM).
    Borges Mde F; Franciscon Pde M; Cambraia TC; Oliveira DM; Ferreira BP; Resende EA; Palhares HM
    Arch Endocrinol Metab; 2015 Dec; 59(6):515-22. PubMed ID: 26421668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effectiveness of Leuprolide acetate therapy every three months in central precocious puberty].
    Mericq G MV; Youlton R R; Willshaw Z ME
    Rev Med Chil; 2006 Jul; 134(7):821-6. PubMed ID: 17130963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty.
    Lee PA; Klein K; Mauras N; Lev-Vaisler T; Bacher P
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3153-9. PubMed ID: 24926950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
    Partsch CJ; Hümmelink R; Peter M; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Horm Res; 1993; 39(3-4):111-7. PubMed ID: 8262471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation.
    Lee PA; Luce M; Bacher P
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1249-1257. PubMed ID: 27740929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final height after combined growth hormone and gonadotrophin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty.
    Lanes R; Gunczler P
    Clin Endocrinol (Oxf); 1998 Aug; 49(2):197-202. PubMed ID: 9828907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated Pre-injection Basal Luteinizing Hormone Concentrations are Common in Girls Treated for Central Precocious Puberty.
    Schubert S; Hvelplund AH; Handberg A; Hagstroem S; Leunbach TL
    J Clin Res Pediatr Endocrinol; 2021 Jun; 13(2):204-211. PubMed ID: 33374097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of leuprolide acetate administered monthly compared to three-monthly in the treatment of central precocious puberty: evaluation at the end of treatment.
    Thaneetrakool T; Aroonparkmongkol S; Numsriskulrat N; Supornsilchai V; Wacharasindhu S; Srilanchakon K
    Front Endocrinol (Lausanne); 2024; 15():1390674. PubMed ID: 38737553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls.
    Brito VN; Latronico AC; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4338-42. PubMed ID: 15356030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum leptin levels in patients with progressive central precocious puberty.
    Heger S; Partsch CJ; Peter M; Blum WF; Kiess W; Sippell WG
    Pediatr Res; 1999 Jul; 46(1):71-5. PubMed ID: 10400137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.